Zejula

6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
GSK's cancer drug combination meets primary goal in late-stage trial
Reuters
Mon, 12/18/23 - 10:10 am
GSK
Zejula
Jemperli
endometrial cancer
clinical trials
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Mon, 10/30/23 - 11:58 am
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Wed, 05/10/23 - 10:18 am
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
GSK told to pay higher royalties to AZ on Zejula sales
Pharmaphorum
Thu, 04/6/23 - 11:37 am
GSK
AstraZeneca
ovarian cancer
Zejula
legal
UK
GSK’s “crown jewels” already look tarnished
EP Vantage
Wed, 11/23/22 - 07:27 am
GSK
Blenrep
Emma Walmsley
daprodustat
gepotidacin
otilimab
Jemperli
Zejula
cabotegravir
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
BioSpace
Sun, 11/13/22 - 07:07 pm
GSK
ovarian cancer
Zejula
PARP inhibitors
FDA
GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial
Clinical Trials Arena
Mon, 09/12/22 - 11:34 pm
GSK
Zejula
ovarian cancer
clinical trials
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report
Fierce Pharma
Mon, 06/7/21 - 08:45 pm
GSK
Tesaro
AstraZeneca
legal
Zejula
Lynparza
With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy
Endpoints
Mon, 10/26/20 - 11:15 am
AnaptysBio
GSK
Tesaro
Zejula
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
Xconomy
Sat, 06/13/20 - 11:27 pm
GSK
oncology
Zejula
niraparib
belantamab mafodotin
dostarlimab
immuno-oncology
GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations
Endpoints
Wed, 04/29/20 - 10:45 pm
GSK
Zejula
Tesara
FDA
ovarian cancer
FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer
BioSpace
Tue, 02/25/20 - 04:59 pm
GSK
Zejula
ovarian cancer
FDA
GSK’s CEO Walmsley aiming for six new approvals in 2020
Pharmaforum
Tue, 01/14/20 - 10:07 am
GSK
Pharma CEOs
Emma Walmsley
JPMHC 2020
Zejula
Trelegy
daprodustat
belantamab mafodotin
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
Mon, 01/13/20 - 11:49 pm
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
Thu, 10/24/19 - 10:08 am
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
GSK’s niraparib meets PFS goal in phase 3 PRIMA trial
Pharmaceutical Business Review
Tue, 10/1/19 - 09:56 am
GSK
clinicial trials
niraparib
Zejula
advanced ovarian cancer
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
Sun, 09/29/19 - 11:57 am
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
Thu, 09/26/19 - 12:33 pm
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula

Pages